---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-016370"
form_type: "8-K"
ticker: "TCMD"
cik: "0001027838"
company_name: "TACTILE SYSTEMS TECHNOLOGY INC"
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:18:01.930726+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tactile Medical Q4 revenue up 21% to $103.6M; acquires LymphaTech for $6.8M

## Summary
- Q4 2025 revenue $103.6M (+21% YoY); net income $10.6M ($0.46 diluted EPS) vs $9.7M ($0.40) in Q4 2024.
- Full year 2025 revenue $329.5M (+12% YoY); adjusted EBITDA $44.8M ($37.1M in 2024).
- FY2026 guidance: revenue $357-365M (8-11% growth), adjusted EBITDA $49-51M.
- Acquired LymphaTech for $6.8M upfront cash plus contingent milestones; adds 3D scanning for lymphedema.
- Repaid $26.3M term loan; repurchased $26.5M stock at avg $12.36 per share.

## SEC filing metadata
- accession: 0001104659-26-016370
- form_type: 8-K
- ticker: TCMD
- cik: 0001027838
- company_name: TACTILE SYSTEMS TECHNOLOGY INC
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1027838/000110465926016370/0001104659-26-016370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1027838/000110465926016370/tcmd-20260217x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-016370
- JSON: https://secwatch.observer/filing/0001104659-26-016370.json
- Plain text: https://secwatch.observer/filing/0001104659-26-016370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.